Combinations Of Mdm2 Inhibitors And Bcl-xl Inhibitors

Abstract

The present disclosure relates to a pharmaceutical combination comprising (a) an Mdm2 inhibitor and (b) a Bcl-xL inhibitor, particularly for use in the treatment of a cancer. This disclosure also relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.


Claims
Download PDF
Document Preview
Document History
  • Publication: May 24, 2018
  • Application: Nov 16, 2017
    WO IB 2017057177 W
  • Priority: Nov 18, 2016
    US US 201662424043 P

Download Citation


Sign in to the Lens

Feedback